Our Pricing

Mounjaro vs Ozempic: Understanding The Differences

Published on: June 03, 2026

When comparing mounjaro vs ozempic uk comparison data, understanding the fundamental differences between these two medications is essential for making an informed treatment choice. Both are injectable medications licensed by the MHRA for weight management, but they work through distinct mechanisms and deliver different clinical outcomes. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these options with transparent pricing and expert guidance.

How Mounjaro and Ozempic Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK, whilst Ozempic contains semaglutide, a single GLP-1 receptor agonist [1]. This fundamental difference in mechanism explains why clinical outcomes vary between the two treatments. Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, creating a dual-pathway effect on appetite regulation and glucose metabolism.

Semaglutide, by contrast, works solely through GLP-1 receptor activation. Both medications slow gastric emptying, reduce appetite, and improve insulin sensitivity, but the additional GIP pathway in tirzepatide appears to enhance metabolic effects [2]. This dual mechanism may explain the superior weight loss outcomes observed in head-to-head trials, though both medications remain highly effective options subject to prescriber assessment.

Clinical Effectiveness: Mounjaro vs Ozempic Weight Loss Results

In the landmark SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1mg (the dose used in Ozempic), patients taking the highest tirzepatide dose achieved an average 15.7kg weight loss compared to 6.7kg with semaglutide over 40 weeks [3]. When tirzepatide was studied at its maximum licensed dose in the SURMOUNT-1 trial, participants achieved up to 22.5% total body weight reduction over 72 weeks [1].

Semaglutide demonstrates robust efficacy in its own right. The STEP 1 trial showed that semaglutide 2.4mg (the dose used in Wegovy, a higher-dose formulation than Ozempic) produced an average 14.9% body weight reduction over 68 weeks [4]. It's important to note that Ozempic is primarily licensed for type 2 diabetes management, whilst Mounjaro has specific licensing for chronic weight management in the UK when prescribed at appropriate doses.

Understanding Trial Data in Real-World Context

Clinical trial results represent average outcomes under controlled conditions and individual responses vary significantly. Your UK prescriber will consider your medical history, current medications, weight loss goals, and any contraindications when recommending between tirzepatide and semaglutide-based treatments. Both medications require commitment to lifestyle modifications including dietary changes and increased physical activity to achieve optimal results.

Dosing Schedules and Administration

Both Mounjaro and Ozempic are administered as once-weekly subcutaneous injections using pre-filled pen devices. Mounjaro follows a structured dose escalation schedule starting at 2.5mg weekly, increasing every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum maintenance dose of 15mg weekly [1]. This gradual titration helps minimise gastrointestinal side effects whilst allowing the body to adapt to the medication.

Ozempic typically begins at 0.25mg weekly for four weeks, then increases to 0.5mg weekly. If additional glycaemic control is needed for diabetes management, the dose may be increased to 1mg weekly after at least four weeks, with a maximum licensed dose of 2mg weekly available in some cases [5]. The slower initial titration with both medications is clinically important for tolerability and adherence.

Injection Technique and Storage

Both medications should be injected into the abdomen, thigh, or upper arm, rotating injection sites weekly to prevent lipodystrophy. Pens must be stored in the refrigerator between 2°C and 8°C before first use, then may be kept at room temperature (not exceeding 30°C) for up to 21 days for Mounjaro or 6 weeks for Ozempic. Never freeze these medications, and always check the solution is clear and colourless before injection.

Side Effects and Tolerability Profile

The most common side effects for both tirzepatide and semaglutide are gastrointestinal in nature, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][5]. These effects typically emerge during dose escalation and often diminish over time as the body adapts. In clinical trials, approximately 10-20% of participants experienced nausea with either medication, though severity varied considerably between individuals.

Tirzepatide appears to have a slightly higher incidence of gastrointestinal side effects compared to semaglutide, likely due to its dual-receptor mechanism, but discontinuation rates remained low in clinical trials [3]. Both medications carry warnings about potential thyroid C-cell tumours based on rodent studies, and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Managing Side Effects Effectively

Eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and not lying down immediately after eating can significantly reduce gastrointestinal symptoms. If side effects become intolerable, your prescriber may recommend staying at your current dose for an additional week or two before escalating further. Never adjust your dose without consulting your healthcare provider, as proper titration is essential for both safety and effectiveness.

Cost Considerations and UK Availability

At Cured Pharmacy, Mounjaro is available from £124.99 per pen, with transparent upfront pricing displayed before your free clinical consultation. Final costs depend on your prescribed dose and treatment duration, which your UK prescriber determines based on your individual clinical assessment. We guarantee the lowest prices in the UK for genuine, MHRA-licensed medications dispensed by our GPhC-registered pharmacy.

Whilst Ozempic is widely prescribed for type 2 diabetes management, Mounjaro offers specific licensing for chronic weight management in adults with a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity. Both medications require prescription from a UK-registered prescriber following thorough medical assessment. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical protocols to ensure patient safety and regulatory compliance.

Which Treatment Is Right for You?

Choosing between Mounjaro and Ozempic depends on multiple factors including your primary treatment goal (weight management versus diabetes control), medical history, previous medication responses, and tolerance for potential side effects. If your primary objective is weight loss and you meet the eligibility criteria, Mounjaro's dual-receptor mechanism may offer enhanced outcomes based on current clinical evidence. However, semaglutide-based treatments remain highly effective and may be more suitable depending on your individual circumstances.

Your UK prescriber will conduct a comprehensive assessment considering your BMI, existing medical conditions, current medications, previous weight loss attempts, and any contraindications before recommending the most appropriate treatment. Both medications require commitment to long-term lifestyle changes and regular monitoring. At Cured Pharmacy, our clinical team provides ongoing support throughout your treatment journey, with discreet packaging, reliable delivery, and access to pharmaceutical advice whenever needed.

Starting Your Treatment Journey

Beginning treatment with either medication involves completing a thorough online consultation that typically takes under three minutes. Our UK-registered prescribers review your medical information, assess your eligibility, and determine the appropriate starting dose. Once approved, your medication is dispensed from our GPhC-registered pharmacy and delivered discreetly to your address. Regular follow-up assessments ensure your treatment remains safe and effective as you progress through dose escalations.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10295), 64–77. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Ozempic 0.25 mg, 0.5 mg, 1 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/9758 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and depend on adherence to prescribed treatment and lifestyle modifications.